Borderline Personality Disorder: Advances In Science And Treatment

Main Category: Schizophrenia
Also Included In: Conferences;  Bipolar
Article Date: 19 Sep 2006 - 0:00 PDT

email to a friend   printer friendly   opinions  

The National Education Alliance for Borderline Personality Disorder (NEA-BPD), the Department of Psychiatry, Mount Sinai School of Medicine, and the National Alliance on Mental Illness New York City Metro are co-sponsoring a one-day conference on Friday, September 29th at The Mount Sinai Medical Center, Hatch Auditorium, Madison Avenue at East 100th Street, from 8 am to 5:00 pm. Registration starts at 7:30 am. The conference title is: Borderline Personality Disorder: Advances in Science and Treatment.

Experts in borderline personality disorder (BPD), including leading professionals, family members and consumers, will present on topics including: new directions on BPD causes and treatments, affective instability (the difference between BPD and bipolar disorder), update on neurobiology, a panel on family research and family and consumer perspectives, suicide and self-injury, impulsivity and medication, and a case study that will be used to discuss and highlight the differences and complementary aspects of two treatment options: transference focused therapy (TFT) and dialectical behavior therapy (DBT). The conference is geared to mental health professionals, allied professionals, family members and recipients of service. This program has been approved by NASW-New York State for 6 contact hours under approval number A-896.

Perry D. Hoffman, Ph.D., President of NEA-BPD and Charlotte M. Fischman, Esq., President of the NAMI-NYC Metro Board will welcome conference attendees. Eric Hollander, M.D., Esther and Joseph Klingenstein Professor and Chair of Psychiatry, Director, Seaver and New York Autism Center, will introduce the all-day conference and will present the plenary session on impulsivity and medication. Other plenary presentations will be given by Larry Siever, M.D., Harold Koenigsberg, M.D., Antonia New, M.D., and Beth Brodsky, Ph.D., Marianne Goodman, M.D., Frank Yeomans, M.D., Ph.D., and Christine Foertsch. Participants in the panel include Perry Hoffman, Ph.D., Dixianne Penney, Dr.P.H., Charlotte M. Fischman, Esq., Coleen Bocuso, and Hillary Eaton, M.Ed.

Borderline personality disorder is a serious mental illness characterized by pervasive instability in moods, interpersonal relationships, self-image, and behavior. This instability often disrupts family and work life, long-term planning, and the individual's sense of self-identity. While less known than schizophrenia or bipolar disorder (manic-depressive illness), BPD is estimated to be at least as common, affecting one percent of adults. Up to 73% of those diagnosed with the disorder have made at least one suicide attempt. Further, approximately 10% of patients with BPD eventually do commit suicide. Thus, persons with BPD are a public health concern of significant magnitude.

###

Contact: Mount Sinai Press Office
The Mount Sinai Hospital / Mount Sinai School of Medicine

• Additional
• References
• Citations